Zobrazeno 1 - 10
of 41
pro vyhledávání: '"moroctocog alfa"'
Autor:
A.Yu. Borozinets, E.V. Gapchenko, K.G. Kopylov, S.N. Farafonova, M.A. Timofeeva, E.E. Shiller, V.V. Lebedev, Immunology named after Dmitry Rogachev, Moscow, Russia, N.I. Zozulya, Dmitry Kudlay, V.M. Chernov, E.P. Ivashkina, O.I. Plaksina, T.V. Asekretova, O.A. Markova
Publikováno v:
Pediatria. Journal named after G.N. Speransky. 100:154-161
The purpose of the study was to assess the efficacy, safety and pharmacokinetics of the moroctocog alfa (Octofactor) in children aged 2-6 with haemophilia A. Materials and methods of research : six patients between 2 and 6 years of age (average age 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c78db7afa429209d8213bce87eb5b84f
https://doi.org/10.24110/0031-403x-2021-100-6-154-161
https://doi.org/10.24110/0031-403x-2021-100-6-154-161
Autor:
Yongqiang Zhao, Binyu Luo, Lihong Xu, Pablo Rendo, Xuefeng Wang, Runhui Wu, Jeremy Rupon, Jing Sun, Depei Wu, Feifei Sun, Francois Huard, Renchi Yang, Yingxue Cathy Liu, Jie Jin, Chenghao Jin, Joan M. Korth-Bradley
Publikováno v:
Journal of Blood Medicine. 11:439-448
Introduction Moroctocog alfa albumin-free cell culture (AF-CC) increases plasma levels of factor VIII (FVIII) activity and, in China, is indicated for the control and prevention of bleeding episodes in patients with hemophilia A. This study aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98d8878ee448057b9b05fd6b78974dec
https://doi.org/10.2147/jbm.s241605
https://doi.org/10.2147/jbm.s241605
Publikováno v:
European Journal of Haematology
Objective To evaluate real‐world outcomes with rVIII‐SingleChain and other commonly used recombinant FVIII (rFVIII) products. Methods Hemophilia treatment centers in Germany (n = 21) contributed patient chart data. Inclusion criteria were prophyl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a86378789ce5db38661f1ccae4bb4a5
https://doi.org/10.1111/ejh.13378
https://doi.org/10.1111/ejh.13378
Publikováno v:
Haemophilia. 27
INTRODUCTION Recombinant coagulation factor VIII (FVIII) products are the standard of care for patients with haemophilia A. The development of modified FVIII products has provided benefit for patients but presented challenges for monitoring FVIII act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061a8d6342ae2eb8d3c31796cb77a7a4
https://doi.org/10.1111/hae.14416
https://doi.org/10.1111/hae.14416
Publikováno v:
Russian Journal of Pediatric Hematology and Oncology. 6:30-47
Relevance. In accordance with the guidelines on the clinical investigation of clotting factor VIII products of the European Medicines Agency and guidelines on pharmacovigilance of the Eurasian Economic Union, after registration of a new drug, it is r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a98ba4cb7c33c5cf815cf0f9102650e0
https://doi.org/10.21682/2311-1267-2019-6-2-30-47
https://doi.org/10.21682/2311-1267-2019-6-2-30-47
Autor:
Romeo-Gabriel Mihaila
Publikováno v:
International Journal of Pharmacology, Phytochemistry and Ethnomedicine. 11:1-6
The current treatment of patients with hemophilia A is safer and more effective than the previous one. Prophylactic substitution involves repeated intravenous administration of plasma-derived factor VIII or recombinant factor VIII products, with inco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62f260c441069aa98f979d96f81bcb8c
https://doi.org/10.18052/www.scipress.com/ijppe.11.1
https://doi.org/10.18052/www.scipress.com/ijppe.11.1
Autor:
Peter William Collins, Elizabeth Chalmers, M Richards, B. Palmer, Mary Mathias, Jayanthi Alamelu, Andrew M. Will, Charles R. M. Hay
Publikováno v:
Haemophilia. 24:896-901
Introduction\ud \ud Factor VIII inhibitor development is currently the most serious complication of the treatment of haemophilia A. Differences in manufacturing and the molecular structure of brands of recombinant factor VIII have led to speculation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b7b726b2f022ebf7522dfa2e14cac4
https://doi.org/10.1111/hae.13551
https://doi.org/10.1111/hae.13551
Autor:
L. Rusen, Jeremy Rupon, Pablo Rendo, Kaan Kavakli, Joanne Fuiman, Joan M. Korth-Bradley, James Baumann, Christine Alvey, Francois Huard, Lynne Smith
Publikováno v:
Haemophilia. 24:604-610
WOS: 000442583600048
PubMed ID: 29582525
IntroductionThe pharmacokinetics (PK), efficacy and safety of moroctocog alfa (AF-CC) have been demonstrated in haemophilia A patients aged 6years. AimThese studies aimed to further describe moroctoc
PubMed ID: 29582525
IntroductionThe pharmacokinetics (PK), efficacy and safety of moroctocog alfa (AF-CC) have been demonstrated in haemophilia A patients aged 6years. AimThese studies aimed to further describe moroctoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d481121f47a0eff06ae5cc64c54cf64
https://doi.org/10.1111/hae.13466
https://doi.org/10.1111/hae.13466
Publikováno v:
Clinical and Translational Science. 11:283-288
An open-label, single-dose, randomized, two-period, crossover study comparing the pharmacokinetics of factor VIII activity in plasma (FVIII:C) after administration of an albumin-free presentation of moroctocog alfa (test) and moroctocog alfa manufact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec7050a0260167a9442b6e94fa6d3dfd
https://doi.org/10.1111/cts.12544
https://doi.org/10.1111/cts.12544
Publikováno v:
Revista de Chimie. 69:3702-3704
Hemophilia A is a hereditary coagulopathy caused by the deficiency of the coagulation factor VIII, whose main complication consists in disabling arthropathy. The most often affected joint is the one of the knee, due to which this article aims at pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d6537aa114f919c392ddeffb7369ba3
https://doi.org/10.37358/rc.18.12.6823
https://doi.org/10.37358/rc.18.12.6823